Looking at the current situation，my country's 13,000 wholesale enterprises withdraw from 10,000，The remaining 3,000 may be an ideal situation。

 

  Recently，Central Committee of the Communist Party of China、The State Council released "& ldquo; Healthy China 2030 & rdquo; Planning Outline" (hereinafter referred to as "Outline")。Among them, pointed out in the pharmaceutical industry，To promote the transformation and upgrade of the medical circulation industry，Improve the concentration of circulation market，Forms a number of multinational large -scale drug circulation enterprises。As of now，There are 13,000 domestic medical circulation enterprises，But less than 3,000 real compliance。

 

  October 29，At the 8th China Pharmaceutical Entrepreneur Annual Conference and 2016 Pharmaceutical Industry Innovation Forum，CFDA (State Food and Drug Administration) deputy director Wu Yan pointed out to the 21st Century Business Herald reporter，80%of our country's wholesale volume is concentrated in the top 100 companies，According to the laws of market economy，Some wholesale companies cannot survive。But the market economy has failed in the field of pharmaceutical wholesale，The prevailing person can't win，Insubitious people can't get rid of。

 

  Wu Yan said，Rectification in the field of circulation must solve the problem of many circulation links，Launched a two -vote system、Strike a ticket，Must reform the whole process，Strengthen supervision，Including the use unit reasonable medication, etc.。According to incomplete statistics，Since 2016，The "Certificate of Quality Management Specification Certification Certificate" (GSP) of stake online sports bettingmore than 200 pharmaceutical business enterprises (GSP) is taken back，or "Drug Business License" was revoked。

 

  Another industry person pointed out，After rectification，A large number of unsatisfactory companies will be eliminated，It will also increase the concentration of circulation market。& ldquo; 135 & rdquo; Planning also points out，During the period of & ldquo; 135 & rdquo;，The nationwide scope will generate super -large pharmaceutical enterprise groups and a large number of nationwide、Regional large backbone drug circulation enterprise，Pharmaceutical distribution enterprises listed by the national small and medium -sized enterprise shares transfer system will increase significantly，The concentration of the drug circulation industry will be further increased。

 

  The pharmaceutical circulation industry is facing challenges

 

  Outline points out，Promote medicine、Medical device circulation enterprises extend the service to the upstream and downstream of the supply chain，Form a new system of modern circulation; standardize pharmaceutical e -commerce，Rich drug circulation channels and development models; promote the application of modern logistics management and technology，Improve the modern circulation network and traceability system of traditional Chinese medicinal materials; implement medical institution drugs、Consumption procurement main position，Encourage joint procurement; build a modern pharmaceutical circulation network throughout the urban and rural areas，Improve the ability of drug supply guarantee in the grassroots and remote areas。

 

  From the perspective of the industry，According to the Outline，The status of the drug circulation industry will be strengthened，But at the same time facing greater challenges，Survival will be the biggest question of most circulating enterprises。It requires drug circulation enterprises to huge scale，Industry concentrated monopoly，Diversified service capabilities，Supply Chain Management Intelligent Feedback，Cost control international level，and form a first -class giant enterprise。

 

  Actually，CFDA is also related to the medical circulation industry for rectification，May in May issued a special rectification announcement on the circulation field。July，National Health and Family Planning Commission、Development and Reform Commission、Ministry of Finance、Ministry of Industry and Information Technology、Ministry of Human Resources and Social Affairs、Business Department、Administration of Industry and Commerce、Taxation General Administration、stake online sports bettingCFDA and other nine major committees jointly issued the "Key Points for the Special Governance Work Points of Injustice in Medical Purchase and Medical Services in 2016"。

 

  On the above forum，CFDA Deputy Director Wu Yan pointed out，CFDA will rectify in the field of circulation and solve the problem of more circulation links，Launched a two -vote system、Strike a ticket，Must reform the whole process，Strengthen supervision，Including the use unit reasonable medication, etc.。& ldquo;，The quality of Chinese drugs must be fundamentally guaranteed，It must be difficult。& rdquo;

 

  In the recent rectification of CFDA on the circulation of drugs，In just one month, nearly a hundred commercial companies have been canceled、Hundreds of commercial companies are included in the strict check object，The storm of rectification continues everywhere。According to incomplete statistics from industry insiders，Since 2016，The "Certificate of Quality Management Specification Certification Certificate" (GSP) of stake online sports bettingmore than 200 pharmaceutical business enterprises (GSP) is taken back，or "Drug Business License" was revoked。

 

  Gu Xin, a professor at the School of Government Management of Peking University, pointed out，After the implementation of the two -vote system，The main business is & ldquo; Voting & rdquo; thousands of pharmaceutical business enterprises will close the door，M & A and reorganization waves in the field of pharmaceutical business are rising.。

 

  Rudo July，Yibai Pharmaceuticals sold 75%of Yibai Pharmaceuticals in CCTLE business，It is clearly stated in the announcement: the reason for sale: changes in the pharmaceutical market environment, especially the two -vote promotion，Company's product sales platform Yibai pharmaceutical function has changed。

 

  An analyst at a pharmaceutical industry pointed out to the 21st Century Business Herald reporter，Under the impact of the two -vote system，The size of the sale of Yibai Pharmaceuticals is not large、Poor profitable enterprises to large commercial circulation companies，Is the general trend，In the future, more companies may gradually withdraw from the circulation field。

 

  Industry concentration further increases

 

  The above analysts point out，The implementation of the two -vote system and other fiscal and tax policies on the ground，The cost of the pharmaceutical factory for & ldquo; channel & rdquo; cost will be highly transparent，Small and medium -sized pharmaceutical circulation enterprises will face the crisis of survival。

 

  For this，There are also worries in the industry，During the integration of commercial companies，A revoked、Log canceling or the number of enterprises will gradually increase due to reduced business，Some agents may directly face the acquisition of upstream companies、The fate of transferring or eliminating the outbound situation。

 

  Actually，If you want My stake betting appto improve the concentration of the circulation market，It will inevitably set off a tide of rectification，To eliminate unsatisfactory companies。Previous，Li Guoqing, Director of CFDA Safety Supervision Department, once pointed out，Looking at the current situation，my country's 13,000 wholesale enterprises withdraw from 10,000，The remaining 3,000 may be an ideal situation。

 

  Wu Yan said，80%of our country's wholesale volume is concentrated in the top 100 companies。According to the laws of market economy，Some wholesale companies will not be able to survive，But in fact these wholesale companies are not only alive，Still live well，This has caused a paradox: the market economy has failed in the field of pharmaceutical wholesale，The prevailing person can't win，Insubitious people can't get rid of。

 

  From the "Outline",，In the future, it requires higher drug circulation enterprises，Actually，Now some companies are actively developing in accordance with the above "Outline"，If you start to embrace advanced modern logistics technology and internal IT management system，Get rid of the previously packed by manpower、Sorting and retrospective backward mode，From the perspective of the industry，This will in turn will squeeze the living space of irregular enterprises，Forcing it to withdraw from the market。

 

  According to the Ministry of Commerce's "2015 Pharmaceutical Distribution Industry Operation Statistical Analysis Report" disclosure，The top 15 in the main business income of the pharmaceutical business company in 2015 is more than 10 billion yuan，The total scale of the 15 companies is close to 50%of the scale of my country's pharmaceutical circulation market。Gradually intensive and alignment to the mature market。

 

  According to the report of the Ministry of Commerce，& ldquo; 135 & rdquo;，The nationwide scope will generate super -large pharmaceutical enterprise groups and a large number of nationwide、Regional large backbone drug circulation enterprise，Pharmaceutical distribution enterprises listed by the national small and medium -sized enterprise shares transfer system will increase significantly，The concentration of the drug circulation industry will be further increased。

 

  At present, the circulation enterprises with annual annual turnover of more than 100 billion are Chinese medicine holding、China Resources Pharmaceutical and Shanghai Medicine。From the perspective of the industry，With the advancement of the policy and the intensification of competition，The drug circulation industry continues to active through capital operation，The signs of big fish eating small fish have begun to appear。Now，Chinese Medicine Holdings、China Resources Pharmaceutical and other companies quickly become industry leaders through mergers and acquisitions。

 

   & ldquo; The major rectification of the circulation industry has caused some pharmaceutical business to start closing or want to withdraw from the market，This is a good stake online sports bettingtime for large commercial groups to grab the site，The future medical circulation industry will have a climax。The future medical circulation industry will have a climax。

 

  As the second largest pharmaceutical distributor in China，China Resources Pharmaceuticals expressed in the prospectus on October 16th，In the field of pharmaceutical distribution and pharmaceutical retail，The company intends to acquire the large distribution network through mergers，Covering the whole country from 2020。This is also one of the uses for raised funds for this time。It is understood，China Resources is currently in contact with multiple acquisition targets。